Aromatase Inhibitors: Potential Reproductive Implications

Mohamed A Bedaiwy, Noha A Mousa, Casper RF, Robert F Casper
Journal of Minimally Invasive Gynecology · 2009 · vol. 16(5) , pp. 533–539 · doi:10.1016/j.jmig.2009.05.009 · PMID:19608462 · W2019619951
review OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper reviews the potential reproductive consequences of aromatase inhibitors, drugs that block estrogen production.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

MEDLINE, EMBASE, Scopus, and Web of Science databases literature search from inception to March 2009 was performed to identify published clinical trials and cohort, observational, and in vitro studies that evaluated the use of aromatase inhibitors in reproductive medicine for indications other than ovulation induction. Aromatase inhibitors are currently being investigated for breast cancer prevention in women at high risk. Aromatase inhibitors may be used for treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention. Current evidence does not support the routine use of aromatase inhibitors for these conditions without prospective controlled trials. Aromatase inhibitor cotreatment can be used to prevent the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment to offer flexibility in initiating this therapy.

My notes (saved in your browser only)

MeSH descriptors

Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Breast Neoplasms Breast Neoplasms Breast Neoplasms Combined Modality Therapy Estrogens Estrogens Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Leiomyoma Leiomyoma Leiomyoma Uterine Neoplasms Uterine Neoplasms Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (5)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:59.677786+00:00
License: CC0 · commercial use OK